

Stock Sentiment Analysis Report

Revvity (RVTY)

Analysis Period: 2026-03-10 to 2026-04-09 (30 days)

Generated: 2026-04-09 09:53:58

Executive Summary


Sentiment analysis for Revvity (RVTY) from 2026-03-10 to 2026-04-09. Analyzed 77 items across FDA and news sources.

Sentiment Breakdown

| Category | Count | Percentage |
|--------------|-----------|---------------|
| Positive | 32 | 41.6% |
| Negative | 19 | 24.7% |
| Neutral | 26 | 33.8% |
| Total | 77 | 100.0% |

Overall Sentiment: NEUTRAL

Sentiment Trend Over Time



Key Findings

No key findings available.

Top Positive Events

| Title | Source | Date | Score |
|---|--------|------------|-------|
| Nephron Research gets more bullish on Revvity, upg... | news | 2026-03-26 | 0.991 |
| [Latest] Global Environmental Mass Spectrometry Ma... | news | 2026-04-02 | 0.859 |
| COVID-19 Tests Market Report 2025: Segments, Share... | news | 2026-03-12 | 0.859 |
| Catabolism of extracellular glutathione supplies c... | news | 2026-03-18 | 0.856 |
| A structure-based mRNA vaccine for Nipah virus in ... | news | 2026-03-12 | 0.852 |

Top Negative Events

| Title | Source | Date | Score |
|--|--------|------------|--------|
| The E3 ubiquitin ligase mechanism specifying targe... | news | 2026-03-18 | -0.778 |
| Feasibility of deep learning-based cancer detectio... | pubmed | 2026-04-09 | -0.660 |
| Ectopic NMDAR expression in cancer unmasks germlin... | news | 2026-03-25 | -0.660 |
| Epigenetics Market to Surpass US \$35.84 Billion by... | news | 2026-03-11 | -0.660 |
| A μ -opioid receptor superagonist analgesic with mi... | news | 2026-04-01 | -0.612 |